The Medicines (Products for Human Use) (Fees) Regulations 2016

This document cites

• Khan v. College of Physicians and Surgeons (Ont.) et al., (1992) 57 O.A.C. 115 (CA)
• Legislative and Regulatory Reform Act 2006
• European Communities Act 1972
• European Union (Amendment) Act 2008
• Finance Act 1973



See all quotations

• Medicines Act 1971
• Health and Medicines Act 1988
• Medicines Act 1968
• Companies Act 2006
• Northern Ireland Act 1998
• Medical Devices (Consequential Amendments - Medicines) Regulations 1994
• Departments (Northern Ireland) Order 1999
• Medical Devices (Consultation Requirements) (Fees) Regulations 1995
• The Medicines (Products for Human Use) (Fees) Regulations 2013
• The Veterinary Medicines Regulations 2008
• Gorchymyn Mesur Llywodraeth Leol (Cymru) 2011 (Cychwyn Rhif 1) 2011
• The Medicines (Advisory Bodies) (No. 2) Regulations 2005
• Medicines (Surgical Materials) Order 1971
• Transfer of Functions (Medicines and Poisons) Order 1999
• European Communities (Designation) Order 1972
• The Companies, Partnerships and Groups (Accounts and Reports) Regulations 2015
• The Medicines for Human Use and Medical Devices (Fees Amendments) (No.2) Regulations 2007
• The Medicines for Human Use (Clinical Trials) Regulations 2004
• The Treaty of Lisbon (Changes in Terminology) Order 2011
• The Human Medicines Regulations 2012
• The Human Medicines (Amendment) Regulations 2013
• The Medicines for Human Use (Clinical Trials) Amendment Regulations 2006
• Regulation (EC) No 219/2009 of the European Parliament and of the Council of 11 March 2009 adapting a number of instruments subject to the procedure referred to in Article 251 of the Treaty to Council Decision 1999/468/EC with regard to the regulatory procedure with scrutiny Adaptation to the regulatory procedure with scrutiny — Part Two
• Directive 2000/70/EC of the European Parliament and of the Council of 16 November 2000 amending Council Directive 93/42/EEC as regards medical devices incorporating stable derivates of human blood or human plasma
• Commission Directive 2009/120/EC of 14 September 2009 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use as regards advanced therapy medicinal products (Text with EEA relevance)
• Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use
• Regulation (EC) No 470/2009 of the European Parliament and of the Council of 6 May 2009 laying down Community procedures for the establishment of residue limits of pharmacologically active substances in foodstuffs of animal origin, repealing Council Regulation (EEC) No 2377/90 and amending Directive 2001/82/EC of the European Parliament and of the Council and Regulation (EC) No 726/2004 of the European Parliament and of the Council (Text with EEA relevance )
• Council Directive 93/41/EEC of 14 June 1993 repealing Directive 87/22/EEC on the approximation of national measures relating to the placing on the market of high- technology medicinal products, particularly those derived from biotechnology
• Regulation (EC) No 596/2009 of the European Parliament and of the Council of 18 June 2009 adapting a number of instruments subject to the procedure referred to in Article 251 of the Treaty to Council Decision 1999/468/EC with regard to the regulatory procedure with scrutiny — Adaptation to the regulatory procedure with scrutiny — Part Four
• Directive 2009/53/EC of the European Parliament and of the Council of 18 June 2009 amending Directive 2001/82/EC and Directive 2001/83/EC, as regards variations to the terms of marketing authorisations for medicinal products (Text with EEA relevance)